Quantinno Capital Management LP Boosts Stake in Boston Scientific Co. (NYSE:BSX)

Quantinno Capital Management LP raised its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 36.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 91,089 shares of the medical equipment provider's stock after acquiring an additional 24,088 shares during the period. Quantinno Capital Management LP's holdings in Boston Scientific were worth $7,633,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BSX. Triad Wealth Partners LLC purchased a new stake in shares of Boston Scientific in the second quarter worth about $26,000. Values First Advisors Inc. purchased a new stake in shares of Boston Scientific during the 3rd quarter worth approximately $28,000. Andra AP fonden bought a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $29,000. E Fund Management Hong Kong Co. Ltd. purchased a new position in shares of Boston Scientific in the third quarter valued at $30,000. Finally, Capital Performance Advisors LLP bought a new stake in Boston Scientific in the third quarter worth $30,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of the firm's stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares in the company, valued at $3,610,038.74. This trade represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 162,777 shares of the company's stock in a transaction on Monday, October 7th. The stock was sold at an average price of $84.63, for a total value of $13,775,817.51. Following the transaction, the chief executive officer now directly owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. The trade was a 9.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 328,157 shares of company stock worth $27,957,676 in the last three months. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Down 0.5 %

Boston Scientific stock traded down $0.46 during midday trading on Friday, hitting $90.07. 3,021,319 shares of the company's stock were exchanged, compared to its average volume of 6,012,767. Boston Scientific Co. has a 12 month low of $54.52 and a 12 month high of $91.93. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The company has a market cap of $132.75 billion, a PE ratio of 74.44, a P/E/G ratio of 2.66 and a beta of 0.80. The firm has a 50-day moving average of $87.27 and a two-hundred day moving average of $81.16.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. The company had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific's revenue was up 19.3% compared to the same quarter last year. During the same period last year, the company posted $0.50 earnings per share. As a group, analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on BSX shares. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a research note on Wednesday, November 27th. Citigroup increased their price target on shares of Boston Scientific from $92.00 to $98.00 and gave the company a "buy" rating in a report on Thursday, October 24th. Sanford C. Bernstein boosted their price objective on Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a research note on Thursday, October 24th. Mizuho raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Finally, Stifel Nicolaus boosted their target price on Boston Scientific from $85.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, October 18th. Four analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $93.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.